And its co-development partner Astellas Pharma US.

To gain access to the meeting call, please dial 416-340-2217 or 866-696-5910 and reference conference 2345242. There will be a separate dial-in line for analysts on which we will respond to questions by the end of the call. The webcast can be accessed through Cardiome’s website at Webcast and telephone replays of the meeting call will be accessible approximately two hours following the completion of the call through September 11, 2009. Please dial 416-695-5800 or 800-408-3053 and enter code 3147267 accompanied by the number sign to access the replay. About KYNAPID KYNAPID Injection, or vernakalant , can be an investigational new drug for the rapid conversion of severe atrial fibrillation to sinus rhythm. Its system of action consists of the selective blockade of multiple ion stations in the center that are regarded as energetic during episodes of atrial fibrillation.And just how many Australians have it. Osteoporosis Australia aims to provide services and osteoporosis details to the grouped community and health professionals, to be able to improve recognition and reduce fractures.

Yaping Yang, Ph.D., Donna M. Muzny, M.Sc., Jeffrey G. Reid, Ph.D., Matthew N. Bainbridge, Ph.D., Alecia Willis, Ph.D., Patricia A. Ward, M.S., Alicia Braxton, M.S., Joke Beuten, Ph.D., Fan Xia, Ph.D., Zhiyv Niu, Ph.D., Matthew Hardison, Ph.D., Richard Person, Ph.D., Mir Reza Bekheirnia, M.D., Magalie S.